loading page

Liver and kidney function in patients with Covid-19 treated with remdesivir
  • +2
  • Sylvia van Laar,
  • M De Boer,
  • Kim Gombert-Handoko,
  • HJ Guchelaar,
  • Juliette Zwaveling
Sylvia van Laar
Leiden University Medical Center
Author Profile
M De Boer
Leiden University Medical Center
Author Profile
Kim Gombert-Handoko
Leiden University Medical Center
Author Profile
HJ Guchelaar
Leiden University Medical Center
Author Profile
Juliette Zwaveling
Leiden University Medical Center
Author Profile

Abstract

For the treatment of Covid-19 patients with remdesivir, poor renal- and liver function were both exclusion criteria in randomized clinical trials (RCTs) and contra-indication for treatment. Also, nephrotoxicity and hepatotoxicity are reported as adverse events. We retrospectively reviewed renal- and liver functions of covid-19 patients who received remdesivir in the 15 days after treatment initiation. Approximately 20% of the patient population met RCT exclusion criteria. In total, 11% of the patients had a decrease in estimated glomerular filtration rate larger than 10 ml/min/1.73m2. Also, 25% and 35% had increased alanine transaminase and aspartate transaminase levels, respectively. However, serious adverse events were limited. Therefore, contra-indications based on kidney- and liver function should not be absolute for remdesivir treatment in patients with Covid-19 if these functions are monitored regularly.

Peer review status:ACCEPTED

11 Jan 2021Submitted to British Journal of Clinical Pharmacology
13 Jan 2021Submission Checks Completed
13 Jan 2021Assigned to Editor
14 Jan 2021Reviewer(s) Assigned
31 Jan 2021Review(s) Completed, Editorial Evaluation Pending
01 Feb 2021Editorial Decision: Revise Minor
02 Mar 20211st Revision Received
03 Mar 2021Submission Checks Completed
03 Mar 2021Assigned to Editor
03 Mar 2021Review(s) Completed, Editorial Evaluation Pending
12 Mar 2021Editorial Decision: Accept